-
Posted by
Two Blokes Jun 16 -
Filed in
Stock
-
5 views
Axpaxli is Ocular's main value driver, targeting a large wet AMD market with a differentiated, sustained-release TKI mechanism. DEXTENZA sales are declining, making Ocular increasingly dependent on Axpaxli's clinical and commercial success. Upcoming Phase 3 data for Axpaxli is a binary catalyst: strong results could double the stock, while failure risks a 70%+ drop.
